Association between Pri-miR-34b/c rs4938723 polymorphism and bladder cancer risk

Abstract

Several studies examined the impact of miR-34b/c rs4938723 polymorphism and cancer risk, but the findings are inconsistent. However, no study has been conducted to inspect the impact of miR-34b/c polymorphism on bladder cancer. This study aimed to assess possible association between rs4938723 polymorphism and bladder cancer risk. This case-control study was done on 136 pathologically proven bladder cancer patients and 144 controls. Genotyping of Pri-miR-34b/c rs4938723 polymorphism was achieved by using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. Our findings did not show any statistically significant differences in genotype and allele frequencies between bladder cancer and controls. Larger sample sizes with diverse ethnicities are required to validate our findings.

Keywords

Pri-miR-34 b/c / bladder cancer / polymorphism / microRNA

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7–30

[2] Shiels MS, Gibson T, Sampson J, Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers[J]. J ClinOncol, 2014, 32(35): 3989–3995

[3] Vermeulen SH, Hanum N, Grotenhuis AJ, Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study[J]. Br J Cancer, 2015, 112(3): 594–600

[4] Burger M, Catto JW, Dalbagni G, Epidemiology and risk factors of urothelial bladder cancer[J]. EurUrol, 2013, 63(2): 234–241

[5] Giedl J, Rogler A, Wild A, TERT core promotor mutations in early-onset bladder cancer[J]. J Cancer, 2016, 7(8): 915–920

[6] Sankhwar M, Sankhwar SN, Bansal SK, Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses[J]. Sci Rep, 2016, 6: 27018

[7] Hua Q, Lv X, Gu X, Genetic variants in lncRNA H19 are associated with the risk of bladder cancer in a Chinese population[J]. Mutagenesis, 2016, 31(5): 531–538

[8] Aben KK, Witjes JA, Schoenberg MP, Familial aggregation of urothelial cell carcinoma[J]. Int J Cancer, 2002, 98(2): 274–278

[9] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281–297

[10] Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer[J]. Nat Rev Cancer, 2006, 6(4): 259–269

[11] He L, Thomson JM, Hemann MT, A microRNA polycistron as a potential human oncogene[J]. Nature, 2005, 435(7043): 828–833

[12] Voorhoeve PM, le Sage C, Schrier M, A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors[J]. Cell, 2006, 124(6): 1169–1181

[13] Li YQ, Lu JH, Bao XM, MiR-24 functions as a tumor suppressor in nasopharyngeal carcinoma through targeting FSCN1[J]. J ExpClin Cancer Res, 2015, 34(1): 130

[14] Ruoming W, Zhen Y, Tengteng Z, Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2[J]. Cancer Gene Ther, 2015, 22(12): 564–572

[15] Glover AR, Zhao JT, Gill AJ, MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma[J]. Oncotarget, 2015, 6(34): 36675–36688

[16] Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research[J]. Nat Rev Cancer, 2010, 10(6): 389–402

[17] Zhu S, Wu H, Wu F, MicroRNA-21 targets tumor suppressor genes in invasion and metastasis[J]. Cell Res, 2008, 18(3): 350–359

[18] Buscaglia LE, Li Y. Apoptosis and the target genes of microRNA-21[J]. Chin J Cancer, 2011, 30(6): 371–380

[19] Hashemi M, Sheybani-Nasab M, Naderi M, Association of functional polymorphism at the miR-502-binding site in the 3′ untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report[J]. TumourBiol, 2014, 35(10): 10375–10379

[20] Zhang S, Qian J, Cao Q, A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population[J]. Mutagenesis, 2014, 29(2): 149–154

[21] Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm differentiation[J]. Development, 1998, 125(24): 4909–4917

[22] Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it![J]. J Cell Physiol, 2010, 222(1): 42–49

[23] Xu Y, Liu L, Liu J, A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma[J]. Int J Cancer, 2011, 128(2): 412–417

[24] Zhu J, Yang L, You W, Genetic variation in miR-100 rs1834306 is associated with decreased risk for esophageal squamous cell carcinoma in Kazakh patients in northwest China[J]. Int J Clin Exp Pathol, 2015, 8(6): 7332–7340

[25] Wang FJ, Ding Y, Mao YY, Associations between hsa-miR-603 polymorphism, lifestyle-related factors and colorectal cancer risk[J]. Cancer Biomark, 2014, 14(4): 225–231

[26] Ji TX, Zhi C, Guo XG, MiR-34b/c rs4938723 polymorphism significantly decreases the risk of digestive tract cancer: meta-analysis[J]. Asian Pac J Cancer Prev, 2015, 16(14): 6099–6104

[27] Chen P, Sun R, Pu Y, Pri-Mir-34b/C and Tp-53 polymorphisms are associated with the susceptibility of papillary thyroid carcinoma: a case-control study[J]. Medicine (Baltimore), 2015, 94(38): e1536

[28] Pan XM, Sun RF, Li ZH, Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer[J]. Genet Test Mol Biomarkers, 2015, 19(4): 198–202

[29] Nowakowska M, Płuciennik E, Wujcicka WI, The correlation analysis of WWOX expression and cancer related genes in neuroblastoma—a real time RT-PCR study[J]. Acta Biochim Pol, 2014, 61(1): 91–97

[30] Tao T, Chen S, Xu B, Association between hsa-miR-34b/c rs4938723 T>C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls[J]. Chin J Cancer Res, 2014, 26(3): 315–322

[31] Liang TJ, Liu HJ, Zhao XQ, Lack of association of MiR-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis[J]. PLoS One, 2013, 8(7): e68588

[32] Yuan F, Sun R, Chen P, Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk[J]. Tumour Biol, 2016, 37(5): 6267–6273

[33] Tong N, Chu H, Wang M, Pri-miR-34b/c rs4938723 polymorphism contributes to acute lymphoblastic leukemia susceptibility in Chinese children[J]. Leuk Lymphoma, 2016, 57(6): 1436–1441

[34] Bensen JT, Tse CK, Nyante SJ, Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study[J]. Cancer Causes Control, 2013, 24(6): 1099–1109

[35] Hashemi M, Bizhani F, Danesh H, MiR-608 rs4919510 C>G polymorphism increased the risk of bladder cancer in an Iranian population[J]. Aims Genet, 2016, 3(4): 212–218.

[36] Hashemi M, Hanafi Bojd H, EskandariNasab E, Association of adiponectin rs1501299 and rs266729 gene polymorphisms with nonalcoholic fatty liver disease[J]. Hepat Mon, 2013, 13(5): e9527

[37] Sanaei S, Hashemi M, Rezaei M, Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk[J]. Biomed Rep, 2016, 5(1): 125–129

[38] Carvalho IN, Reis AH, Dos Santos AC, A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma[J]. Cancer Biomark, 2017, 18(3): 313–317

[39] Li L, Wu J, Sima X, Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma[J]. Tumour Biol, 2013, 34(3): 1919–1923

[40] Liu CJ, Ma XW, Zhang XJ, pri-miR-34b/c rs4938723 polymorphism is associated with hepatocellular carcinoma risk: a case-control study in a Chinese population[J]. Int J Mol Epidemiol Genet, 2017, 8(1): 1–7

[41] Chen LL, Shen Y, Zhang JB, Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma[J]. Genet Mol Res, 2016, 15(4)

[42] Son MS, Jang MJ, Jeon YJ, Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma[J]. Gene, 2013, 524(2): 156–160

[43] Yang C, Ma X, Liu D, Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population[J]. Tumour Biol, 2014, 35(12): 12545–12554

[44] Wu Y, Jia Z, Cao D, Predictive value of MiR-219–1, MiR-938, MiR-34b/c, and MiR-218 polymorphisms for gastric cancer susceptibility and prognosis[J]. Dis Markers, 2017, 20174731891.

[45] Zhang J, Huang X, Xiao J, Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations[J]. PLoS One, 2014, 9(6): e100055

[46] Oh J, Kim JW, Lee BE, Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer[J]. Oncol Rep, 2014, 31(2): 995–1002

[47] Gao LB, Li LJ, Pan XM, A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer[J]. Biol Chem, 2013, 394(3): 415–420

[48] Hashemi M, Danesh H, Bizhani F, Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer[J]. Cancer Biomark, 2017, 18(2): 155–159

[49] Tong N, Chu H, Wang M, Pri-miR-34b/c rs4938723 polymorphism contributes to acute lymphoblastic leukemia susceptibility in Chinese children[J]. Leuk Lymphoma, 2015, 57(6): 1436–1441

[50] Hashemi M, Bahari G, Naderi M, Pri-miR-34b/c rs4938723 polymorphism is associated with the risk of childhood acute lymphoblastic leukemia[J]. Cancer Genet, 2016, 209(11): 493–496

Acknowledgment

This paper was funded by a research grant (#8067) from Zahedan University of Medical Sciences.

RIGHTS & PERMISSIONS

2018 2018 by the Journal of Biomedical Research.